An updated ACOG practice advisory issued in 2025 has clarified and slightly extended the recommended window for initiating low-dose aspirin prophylaxis in women at high risk of preeclampsia, building on the foundational ASPRE trial evidence. For pregnant women across Dubai — a city with one of the world’s most diverse and often higher-risk obstetric populations — this update has direct, practical relevance. For a city like Dubai, where antenatal bookings sometimes occur slightly later than the international ideal due to relocation, work travel, or simply busy schedules, understanding exactly where the boundaries of effective intervention now lie can make a tangible difference to how a pregnancy is managed from the very first specialist appointment.
What Changed
Previous guidance recommended aspirin initiation strictly between 11 and 14 weeks. The 2025 update confirms that initiation up to 16 weeks still confers meaningful risk reduction in women identified as high-risk who were not assessed in the earlier window, while reaffirming that earlier initiation (closer to 11–12 weeks) produces the greatest reduction in preterm preeclampsia — approximately 60–65%.
Why Risk Screening Timing Matters in Dubai
Dubai’s obstetric population includes a high proportion of women with risk factors that elevate preeclampsia risk: advanced maternal age, elevated BMI, pre-existing hypertension, and family history patterns common among South Asian and Gulf-region populations. Combined first-trimester screening — incorporating maternal risk factors, uterine artery Doppler, and PlGF blood testing — remains the most accurate method of identifying which women will benefit most from aspirin prophylaxis.
What This Means for Expecting Mothers
Women booking antenatal care in Downtown Dubai, Business Bay, or Jumeirah should ensure their first booking appointment occurs early enough — ideally before 10 weeks — to allow time for first-trimester combined screening and, where indicated, timely commencement of aspirin. Women who book later than 14 weeks are not without options under the updated guidance, but earlier engagement remains clinically preferable.
The Broader Trend in Preeclampsia Prevention
This update reflects a broader trend in obstetric research: moving from reactive management of preeclampsia toward proactive, individualised risk stratification in the first trimester. Combined with growing use of PlGF-based blood tests for diagnosis once symptoms appear, the overall direction of preeclampsia care is toward earlier, more precise, and more personalised intervention.
Putting This Research Into Context
It is also worth noting what has not changed alongside this update: aspirin prophylaxis is only one part of a comprehensive preeclampsia prevention strategy. Adequate calcium intake, blood pressure monitoring at every antenatal visit, and prompt reporting of symptoms such as headache, visual disturbance, or swelling remain equally important regardless of aspirin use. Women in Dubai should view this updated aspirin guidance as one component of a broader, individualised risk-reduction plan developed with their obstetrician, not a standalone solution.
How This Compares to Current Standard Practice in Dubai
Leading obstetric practices across Dubai already incorporate first-trimester combined screening as standard practice for risk-stratifying preeclampsia, reflecting the city’s overall alignment with international best-practice obstetric care. This update refines the precise window for aspirin initiation rather than introducing an entirely new concept to local practice.
Frequently Asked Questions
Is it too late for aspirin if I am already 15 weeks pregnant?
Who is considered high risk for preeclampsia in Dubai?
Does this update change anything for women already taking aspirin in pregnancy?
Conclusion
Staying current with evolving preeclampsia prevention guidance can meaningfully change pregnancy outcomes. Women across Dubai are encouraged to book early antenatal care with a specialist who incorporates the latest international evidence into every pregnancy risk assessment.
Sources & References
This article references recently published research and evolving guidance from peer-reviewed journals and the following recognised authorities in women’s health, current as of the time of writing:
- Royal College of Obstetricians and Gynaecologists (RCOG) — rcog.org.uk
- American College of Obstetricians and Gynecologists (ACOG) — acog.org
- International Federation of Gynecology and Obstetrics (FIGO) — figo.org
- World Health Organization (WHO) — who.int
- National Institute for Health and Care Excellence (NICE, UK) — nice.org.uk
- American Society for Reproductive Medicine (ASRM) — asrm.org
- European Society of Human Reproduction and Embryology (ESHRE) — eshre.eu
⚠ IMPORTANT DISCLAIMER
This article is provided for general knowledge and reference purposes only and summarises recent research findings. It is not a substitute for professional medical advice, diagnosis, or treatment.
No medication, treatment, or change to your healthcare should be undertaken based on this content without first consulting a qualified doctor. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition.
Consult Dr. Ruby Rashmi
Specialist Obstetrician & Gynecologist, Dubai. Book an early antenatal consultation and receive pregnancy care based on the latest international evidence and personalised risk assessment.
